Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 18, Issue 12, 2016, Pages 1244-1252

  Paul, S K ^a   Shaw, J E ^b   Montvida, O ^a,c   Klein, K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

body mass index; glycaemic control; insulin initiation; type 2 diabetes; weight change

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ELECTRONIC MEDICAL RECORD; EVALUATION STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; ICD-9; INSULIN TREATMENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; TREATMENT DURATION; TREATMENT PLANNING; UNITED STATES; WEIGHT CHANGE; WEIGHT GAIN; AGED; BODY WEIGHT; CASE CONTROL STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; FOLLOW UP; METABOLISM; MORBID OBESITY; RETROSPECTIVE STUDY;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OBESITY; OBESITY, MORBID; OVERWEIGHT; RETROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 84992503607     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12761     Document Type: Article

References (17)

1. Ishii H, Iwamoto Y, Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes and Needs (DAWN) JAPAN study. PLoS One. 2012;7:e36361.
2. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753–1760.
3. Alvarsson M, Sundkvist G, Lager I, et al. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab. 2008;10:421–429.
4. Wang Z, York NW, Nichols CG, Remedi MS. Pancreatic beta cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab. 2014;19:872–882.
5. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38:316–322.
6. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes–causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799–812.
7. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:1–10.
8. Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18:401–409.
9. Wang H, Ni YF, Li HZ, Yang S, Feng B. Effects of insulin monotherapy on body weight, composition, and fat distribution in newly diagnosed patients with type 2 diabetes mellitus. J Diabetes. 2013;5:146–148.
10. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2011;13:1008–1019.
11. Paul S, Thorsted BL, Wolden M, Klein K, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular diabetology. 2015;14:1.
12. Kamal KM, Chopra I, Elliott JP, Mattei TJ. Use of electronic medical records for clinical research in the management of type 2 diabetes. Res Social Adm Pharm. 2014;10:877–884.
13. Herrin J, da Graca B, Nicewander D, et al. The effectiveness of implementing an electronic health record on diabetes care and outcomes. Health Serv Res. 2012;47:1522–1540.
14. Hansen RA, Farley JF, Maciejewski ML, Ye X, Qian C, Powers B. Real-world utilization patterns and outcomes of colesevelam HCL in the ge electronic medical record. BMC Endocr Disord. 2013;13:24.
15. Levin P, Wei W, Miao R, et al. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Diabetes Obes Metab. 2015;17:245–253.
16. Davis KL, Tangirala M, Meyers JL, Wei W. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin. 2013;29:1083–1091.
17. Balkau B, Home PD, Vincent M, Marre M, Freemantle N. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care. 2014;37:2108–2113.